Herrmann S M, Whatling C, Brand E, Nicaud V, Gariepy J, Simon A, Evans A, Ruidavets J B, Arveiler D, Luc G, Tiret L, Henney A, Cambien F
Institut National de la Santé et de la Recherche Médicale (INSERM) SC7/U525, Paris, France.
Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):2386-93. doi: 10.1161/01.atv.20.11.2386.
The matrix Gla protein (MGP) is an important inhibitor of vessel and cartilage calcification that is strongly expressed in human calcified, atherosclerotic plaques and could modulate plaque calcification and coronary heart disease risk. Using a genetic approach, we explored this possibility by identifying polymorphisms of the MGP gene and testing their possible association with myocardial infarction (MI) and plaque calcification. Eight polymorphisms were identified in the coding and 5'-flanking sequences of the MGP gene. All polymorphisms were investigated in 607 patients with MI and 667 control subjects recruited into the ECTIM Study (Etude Cas-Témoins de l'Infarctus du Myocarde) and in 717 healthy individuals with echographically assessed arterial calcification and atherosclerosis who were participating in the AXA Study. In the ECTIM Study, alleles and genotypes were distributed similarly in patients and controls in the whole study group; in only 1 subgroup of subjects defined as being at low risk for MI were the concordant A-7 and Ala 83 alleles more frequent in patients with MI than in controls (P<0.003). In the AXA Study among subjects with femoral atherosclerosis, the same alleles were more common in the presence than the absence of plaque calcification (P<0.025). The other MGP polymorphisms were not associated with any investigated clinical phenotype. Transient transfection experiments with allelic promoter-reporter gene constructs and DNA-protein interaction assays were carried out to assess possible in vitro functionality of the promoter variants detected at positions -814, -138, and -7 relative to the start of transcription. When compared with the -138 T allele, the minor -138 C: allele consistently conferred a reduced promoter activity of -20% (P<0.0001) in rat vascular smooth muscle cells and of -50% (P<0.004) in a human fibroblast cell line, whereas the other polymorphisms, including -7, displayed no evidence of in vitro functionality. We conclude that the A-7 or Ala 83 alleles of the MGP gene may confer an increased risk of plaque calcification and MI; however, the observed relationships are weak or limited to subgroups of patients and therefore need confirmation.
基质γ-羧基谷氨酸蛋白(MGP)是血管和软骨钙化的重要抑制剂,在人类钙化的动脉粥样硬化斑块中强烈表达,并可调节斑块钙化及冠心病风险。我们采用遗传学方法,通过鉴定MGP基因的多态性并检测其与心肌梗死(MI)及斑块钙化的可能关联,来探究这种可能性。在MGP基因的编码序列和5'-侧翼序列中鉴定出8个多态性位点。在ECTIM研究(心肌梗死病例对照研究)招募的607例MI患者和667例对照受试者,以及参与AXA研究的717例经超声评估有动脉钙化和动脉粥样硬化的健康个体中,对所有多态性位点进行了研究。在ECTIM研究中,整个研究组的患者和对照中,等位基因和基因型的分布相似;仅在定义为MI低风险的1个亚组受试者中,一致的A-7和Ala 83等位基因在MI患者中比在对照中更常见(P<0.003)。在AXA研究中,在患有股动脉粥样硬化的受试者中,相同的等位基因在有斑块钙化的情况下比没有斑块钙化时更常见(P<0.025)。其他MGP多态性与任何研究的临床表型均无关联。进行了等位基因启动子-报告基因构建体的瞬时转染实验及DNA-蛋白质相互作用分析,以评估在相对于转录起始位点-814、-138和-7位置检测到的启动子变体可能的体外功能。与-138 T等位基因相比,次要的-138 C等位基因在大鼠血管平滑肌细胞中始终使启动子活性降低20%(P<0.0001),在人成纤维细胞系中降低50%(P<0.004),而包括-7在内的其他多态性未显示出体外功能的证据。我们得出结论,MGP基因的A-7或Ala 83等位基因可能增加斑块钙化和MI的风险;然而,观察到的关系较弱或仅限于患者亚组,因此需要进一步证实。